title: Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.
abstract: BACKGROUND
  This study was performed to determine the efficacy of gemcitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma (ACA).
  
  
  METHODS
  Pancreatic ACA patients with previously untreated advanced or metastatic disease were enrolled in a phase II study of gemcitabine and oxaliplatin. Oxaliplatin was given i.v. on day 1 and gemcitabine i.v. on days 1 and 8 of a 3-week cycle. The primary end point of the trial was 6-month survival. Secondary end points included response rate, overall survival, median time to progression and toxicity.
  
  
  RESULTS
  A total of 47 patients were enrolled, 46 of whom were evaluable. Of those patients assessed for the primary end point 50% lived for > or =6 months. The median time to progression was 4.53 months. Five confirmed responses were seen with a median duration of response of 2.7 months. Overall, the treatment was well tolerated. However, one patient died as a result of treatment-related hemolytic uremic syndrome.
  
  
  CONCLUSIONS
  Gemcitabine and oxaliplatin, at doses of 1000 mg/m(2) and 100 mg/m(2), respectively, showed moderate activity in patients with pancreatic ACA. Based on the results of this study further evaluation of this combination is warranted.
authors.affiliation: Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA. alberts.steven@mayo.edu
authors.forename: S R
authors.initials: SR
authors.lastname: Alberts
authors.forename: P M
authors.initials: PM
authors.lastname: Townley
authors.forename: R M
authors.initials: RM
authors.lastname: Goldberg
authors.forename: S S
authors.initials: SS
authors.lastname: Cha
authors.forename: D J
authors.initials: DJ
authors.lastname: Sargent
authors.forename: D F
authors.initials: DF
authors.lastname: Moore
authors.forename: J E
authors.initials: JE
authors.lastname: Krook
authors.forename: H C
authors.initials: HC
authors.lastname: Pitot
authors.forename: T R
authors.initials: TR
authors.lastname: Fitch
authors.forename: M
authors.initials: M
authors.lastname: Wiesenfeld
authors.forename: J A
authors.initials: JA
authors.lastname: Mailliard
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018450:Disease Progression; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013534:Survival; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000093542:Gemcitabine